Physician profile
Stephen H Hand
NPI 1144225566
$8,326.60
in general payments reported to CMS, 2019-2025
52 companies · $2,920 in 2025
The $2,920 reported for 2025 was more than what 91% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,514 · 2020: $714 · 2021: $483 · 2022: $491 · 2023: $1,004 · 2024: $1,200 · 2025: $2,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,948 · Travel and Lodging: $1,082 · Education: $93.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,948.43 |
| Travel and Lodging | $1,081.60 |
| Education | $93.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,426.08 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $817.45 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $726.40 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $607.33 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $561.15 | 2019-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $347.98 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Grifols USA, LLC | $325.64 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Electromed, INC. | $312.46 | 2019-2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $284.50 | 2020-2025 | Glassia, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $273.85 | 2023-2025 | Dupixent |
| Insmed, INC. | $257.29 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $240.56 | 2019-2025 | Zerbaxa, Recarbrio |
| Axsome Therapeutics, INC. | $218.46 | 2023-2025 | Sunosi |
| Genzyme Corporation | $202.37 | 2021-2025 | |
| Harmony Biosciences LLC | $156.08 | 2020-2025 | Wakix |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.